Titre :
  • HER-2 amplification and topoisomerase IIα gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil
Auteur : Di Leo, Angelo ; Gancberg, David ; Larsimont, Denis ; Tanner, Minna ; Järvinen, Tero ; Rouas, Ghizlane ; Dolci, Stella ; Leroy, Jean-Yves ; Paesmans, Marianne ; Isola, Jorma ; Piccart-Gebhart, Martine
Informations sur la publication : Clinical cancer research, 8, 5, (page 1107-1116)
Statut de publication : Publié, 2002
Sujet CREF : Cancérologie
Sciences bio-médicales et agricoles
Mots-clés MeSH : Aged
Anthracyclines -- administration & dosage
Antigens, Neoplasm
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Biomarkers, Tumor -- genetics
Breast Neoplasms -- drug therapy -- genetics -- pathology
Clinical Trials, Phase III as Topic
Cyclophosphamide -- administration & dosage
DNA Topoisomerases, Type II -- genetics
DNA-Binding Proteins
Disease-Free Survival
Female
Fluorouracil -- administration & dosage
Gene Amplification
Humans
In Situ Hybridization, Fluorescence
Lymph Nodes -- pathology
Methotrexate -- administration & dosage
Middle Aged
Mutation
Predictive Value of Tests
Randomized Controlled Trials as Topic
Receptor, ErbB-2 -- genetics
Treatment Outcome
Note : SCOPUS: ar.j
Langue :
  • Anglais
Identificateurs : urn:issn:1078-0432 
info:pmid/12006526
VX-005569